Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial

BACKGROUND: There is limited data on results of central re-testing of samples from patients with invasive breast cancer categorised in their local hospital laboratories as oestrogen receptor (ER) positive and human epidermal growth factor receptor homologue 2 (HER2) negative. METHODS: The Optimal Pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Pinder, S E, Campbell, A F, Bartlett, J M S, Marshall, A, Allen, D, Falzon, M, Dunn, J A, Makris, A, Hughes-Davies, L, Stein, R C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379140/
https://www.ncbi.nlm.nih.gov/pubmed/28222072
http://dx.doi.org/10.1038/bjc.2017.28

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379140/
https://www.ncbi.nlm.nih.gov/pubmed/28222072
http://dx.doi.org/10.1038/bjc.2017.28

Ejemplares similares